amp-224
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01352884)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297570 ↗
Also known as
- amp-224
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02298946 | Phase 1 | Nov 13, 2014 | National Cancer Institute (NCI) |
| NCT01352884 | Phase 1 | Mar 1, 2011 | GlaxoSmithKline, MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2011 |
| MedImmune | For profit | 1 | 1 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1